Validation of ERCC1-XPF Immunodetection – Letter
Authors:
- 28 April 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (9) , 3851-3852
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapyLung Cancer, 2009
- Immunodetection of DNA Repair Endonuclease ERCC1-XPF in Human TissueCancer Research, 2009
- First Reported Patient with Human ERCC1 Deficiency Has Cerebro-Oculo-Facio-Skeletal Syndrome with a Mild Defect in Nucleotide Excision Repair and Severe Developmental FailureThe American Journal of Human Genetics, 2007
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006